Company Overview

Nyrada is a clinical stage drug discovery and development company focused on innovative Transient Receptor Potential Canonical (TRPC) ion channel blockers.  We are listed on the Australian Securities Exchange (ASX) under the ticker ASX:NYR.

Nyrada’s vision is to become a high growth pharmaceutical company specialising in drug discovery and early-stage drug development. Our drug development programs focus on areas of substantial unmet clinical need where few if any, effective or well-tolerated therapies exist.

Nyrada is developing Xolatryp, a first-in-class neuroprotection and cardioprotection treatment.

In February 2024, Nyrada announced preclinical stroke study results showing that Xolatryp achieved a statistically significant neuroprotective effect, rescuing 42% of brain tissue in the penumbra region of treated animals.

In October 2024, Nyrada announced the results of a preclinical coronary heart disease study which showed that Xolatryp provided an 86% cardioprotective effect following myocardial ischemic-reperfusion injury, a leading cause of tissue damage when blood flow is restored to the heart after injury.

In March 2025, Nyrada commenced its first-in-human Phase Ia clinical trial to assess the safety, tolerability, and pharmacokinetics of Xolatryp in healthy human volunteers.